MITOMYCIN for Bladder transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 33 adverse event reports in the FDA FAERS database where MITOMYCIN was used for Bladder transitional cell carcinoma.
Most Reported Side Effects for MITOMYCIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 292 | 13.8% | 27 | 80 |
| Drug ineffective | 117 | 5.5% | 33 | 26 |
| Diarrhoea | 116 | 5.5% | 14 | 55 |
| Nausea | 100 | 4.7% | 10 | 44 |
| Neutropenia | 96 | 4.6% | 16 | 34 |
| Thrombocytopenia | 94 | 4.5% | 13 | 32 |
| Fatigue | 88 | 4.2% | 6 | 26 |
| Disease progression | 86 | 4.1% | 28 | 12 |
| Rash | 67 | 3.2% | 4 | 10 |
| Vomiting | 66 | 3.1% | 7 | 32 |
| Pancytopenia | 64 | 3.0% | 15 | 33 |
| Febrile neutropenia | 59 | 2.8% | 8 | 42 |
| Pyrexia | 58 | 2.8% | 4 | 26 |
| Urinary tract infection | 58 | 2.8% | 3 | 25 |
| Mucosal inflammation | 56 | 2.7% | 8 | 17 |
Other Indications for MITOMYCIN
Transitional cell cancer of the renal pelvis and ureter (322)
Product used for unknown indication (294)
Anal cancer (143)
Anal squamous cell carcinoma (118)
Bladder cancer (94)
Hepatocellular carcinoma (59)
Transitional cell carcinoma (35)
Open angle glaucoma (33)
Squamous cell carcinoma (30)
Metastases to peritoneum (27)
Other Drugs Used for Bladder transitional cell carcinoma
GEMCITABINE (335)
CISPLATIN (252)
PEMBROLIZUMAB (251)
ATEZOLIZUMAB (195)
CARBOPLATIN (146)
BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN (119)
AVELUMAB (104)
DURVALUMAB (88)
NIVOLUMAB (80)
ENFORTUMAB VEDOTIN-EJFV (68)